Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer

References

• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182–1186.
   PubMed Web of Science ®Google Scholar
• Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3(7):643–651.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Vaupel P. Pathophysiological basis for the formation of the tumor microenvironment. Front Oncol 2016;6:66.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989;49(23):6449–6465.
   PubMed Web of Science ®Google Scholar
• McDonald DM, Choyke PL. Imaging of angiogenesis: From microscope to clinic. Nat Med 2003;9(6):713–725.
   PubMed Web of Science ®Google Scholar
• Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993;66(783):181–196.
   PubMed Web of Science ®Google Scholar
• Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333(26):1757–1763.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11(2Pt 1):416–420.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res 2009;335(1):241–248.
   PubMed Web of Science ®Google Scholar
• Siemann DW. Tumor vasculature: A target for anticancer therapies. Chichester (England): John Wiley & Sons, Ltd 2006;pp 1–8.
   Google Scholar
• Yadav L, Puri N, Rastogi V, Satpute P, Sharma V. Tumour angiogenesis and angiogenic inhibitors: A review. J Clin Diagn Res 2015;9(6):Xe01–xe05.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 2005;62(3):846–853.
   PubMed Web of Science ®Google Scholar
• Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications. Oncologist 2000;5(Suppl 1):11–15.
   PubMedGoogle Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 20039(6):669–676.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438(7070):967–974.
   PubMed Web of Science ®Google Scholar
• Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: An update. Pharmacotherapy 2012;32(12), 1095–111.
   PubMed Web of Science ®Google Scholar
• Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003;9(6):677–684.
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al.. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 200410(2):145147.
   Web of Science ®Google Scholar
• Wedge SR, KendrewJ, Hennequin LF, Valentine PJ, Barry ST, Brave SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65(10):4389–400.
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99(17):11393–11398.
   PubMed Web of Science ®Google Scholar
• Bouis D, Kusumanto Y, Meijer C, Mulder NH, Hospers GA. A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res 2006;53(2):89–103.
   PubMed Web of Science ®Google Scholar
• Raica M, Cimpean AM. Platelet-derived growth factor (PDGF)/PDGF receptors (PDGFR) axis as target for antitumor and antiangiogenic therapy. Pharmaceuticals (Basel) 20103(3):572–599.
   PubMedGoogle Scholar
• Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009;9(5):639–651.
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284(5422):1994–1998.
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007;6(4):273–286.
   PubMed Web of Science ®Google Scholar
• Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2(10):727–739.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007;12(3):356–361.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733–4740.
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740–745.
   PubMed Web of Science ®Google Scholar
• NIH. Website: Bevacizumab: second-line treatment of glioblastoma. Available at https://www.cancer.gov/about-cancer/treatment/drugs/fda-bevacizumab–Anchor-Glioblastoma (accessed July 2017).
   Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383(9911):31–39.
   PubMed Web of Science ®Google Scholar
• NIH. Website: Ramucirumab: Approved for gastric or gastroesophageal junction adenocarcinoma. Available at https://www.cancer.gov/about-cancer/treatment/drugs/fda-ramucirumab–anchor-single (accessed July 2017).
   Google Scholar
• Fabi A, Russillo M, Ferretti G, Metro G, Nistico C, Papaldo P, et al. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: Efficacy in combination with hormonal therapy. BMC Cancer 2012;12:482.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29(28):3798–804.
   PubMed Web of Science ®Google Scholar
• Aravantinos G, Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: A systematic review. J Ovarian Res 2014;7:57.
   PubMed Web of Science ®Google Scholar
• Horn L, Sandler A. Chemotherapy and antiangiogenic agents in non-small-cell lung cancer. Clin Lung Cancer 2007;8(Suppl 2);S68–73.
   PubMed Web of Science ®Google Scholar
• Konda B, Shum H, Rajdev L. Anti-angiogenic agents in metastatic colorectal cancer. World J Gastrointest Oncol 2015;7(7):71–86.
   PubMed Web of Science ®Google Scholar
• Teng LS, Jin KT, He KF, Wang HH, Cao J, Yu DC. Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment. J Chin Med Assoc 2010;73(6):281–288.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335–2342.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499–3506.
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666–2676.
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792–799.
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29(30):3968–3976.
   PubMed Web of Science ®Google Scholar
• Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA, et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 2011;29(15):1997–2003.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Bajetta E, ValleJ, Kohne CH, Hecht JR, Moore M, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 2011;29(15):2004–2010.
   PubMed Web of Science ®Google Scholar
• Hodi FS, LawrenceD, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014;2(7):632–642.
   PubMed Web of Science ®Google Scholar
• Sznol MM,   DF, Jones SF, Mier JW, Waterkamp D, Rossi C, Wallin J, et al. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2015;33:(suppl 7):410–410.
   Web of Science ®Google Scholar
• Li D, Williams JI, Pietras RJ. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene 2002;21;(18):28052814.
   Web of Science ®Google Scholar
• Ma J, Waxman DJ. Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res 2009;15(2):578–588.
   PubMed Web of Science ®Google Scholar
• DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and practice of oncology. Lippincott-Raven: Philadelphia 1997, (5th Edition).
   Google Scholar
• Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66(24):11520–11539.
   PubMed Web of Science ®Google Scholar
• Mazeron R, Anderson B, Supiot S, Paris F, Deutsch E. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Cancer Treat Rev 2011;37(6):476–486.
   PubMed Web of Science ®Google Scholar
• Kleibeuker EA, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL. Combining angiogenesis inhibition and radiotherapy: A double-edged sword. Drug Resist Updat 2012;15(3):173–182.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):709–722.
   PubMed Web of Science ®Google Scholar
• Cubillo A, Hernando-Requejo O, Garcia-Garcia E, Rodriguez-Pascual J, De Vicente E, Morelli, P, et al.. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. Am J Clin Oncol 2014;37(2);117–121.
   PubMed Web of Science ®Google Scholar
• Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys 200768(2):472–428.
   PubMed Web of Science ®Google Scholar
• Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T, Ballestrero A, et al. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 2012;15(1):141–150.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014370(8)699–708.
   PubMed Web of Science ®Google Scholar
• Morganti AG, Mignogna S, Caravatta L, Deodato F, Macchia G, Plantamura NM, et al. FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase I-II study. J Chemother 2014;26(6):353–358.
   PubMed Web of Science ®Google Scholar
• Yao M, Galanopoulos N, Lavertu P, Fu P, Gibson M, Argiris A, et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck 2015;37(11):1665–1671.
   PubMed Web of Science ®Google Scholar
• Blaszkowsky LS, Ryan DP, Szymonifka J, Borger DR, Zhu AX, Clark JW, et al. Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Ann Oncol 2014;25(1):121–126.
   PubMed Web of Science ®Google Scholar
• Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National cancer institute of Canada clinical trials group study BR.20. J Clin Oncol 2007;25(27):4278–4284.
   PubMed Web of Science ®Google Scholar
• Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005;65(9):3643–3655.
   PubMed Web of Science ®Google Scholar
• Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity. Clin Cancer Res 2004;10(24):8587–8593.
   PubMed Web of Science ®Google Scholar
• Zips D, Krause M, Hessel F, Westphal J, Bruchner K, Eicheler W, et al. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res 2003;23(5a):3869–3876.
   PubMed Web of Science ®Google Scholar
• Woglom WH. A critique of tumour resistance. J Cancer Res 1923;7:283–311.
   Google Scholar
• Boyland E, Boyland ME. Studies in tissue metabolism: The action of colchicine and B. typhosus extract. Biochem J 1937;31(3):454–460.
   PubMedGoogle Scholar
• Siemann DW. Therapeutic strategies that selectively target and disrupt established tumor vasculature. Hematol Oncol Clin North Am 2004;18(5):1023–1037, viii.
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5(6):423–435.
   PubMed Web of Science ®Google Scholar
• Salmon BA, Siemann DW. Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys 2007;68:(1):211–217.
   PubMed Web of Science ®Google Scholar
• Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 2011;37(1):63–74.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Horsman MR. Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol Ther 2015;153:107–124.
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents. Br J Cancer Suppl 1996;27:S86–88.
   PubMedGoogle Scholar
• Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57(10):1829–1834.
   PubMed Web of Science ®Google Scholar
• Clémenson C, Chargari C, Deutsch E. Combination of vascular disrupting agents and ionizing radiation. Crit Rev Oncol / Hematol 2013;86(2):143–160.
   PubMed Web of Science ®Google Scholar
• Nepali K, Ojha R, Lee HY, Liou JP. Early investigational tubulin inhibitors as novel cancer therapeutics. Expert Opin Investigational Drugs 2016;25(8):917–936.
   PubMed Web of Science ®Google Scholar
• Wu XY, Ma W, Gurung K, Guo CH. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy. J Formosan Med Assoc 2013;112(3):115–124.
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999;80(Suppl 1):57–64.
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Curr Opin Investig Drugs 2006;7(6):522–528.
   PubMedGoogle Scholar
• Siemann DW, Horsman MR. Small molecule vascular distrupting agents in cancer therapy. Ellis, L. M., Teicher, G. Eds. Towaha: Humana 2008;pp 297–310.
   Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10(2):415–427.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;54(5):1512–1517.
   PubMed Web of Science ®Google Scholar
• Siemann DW. Vascular targeting agents. Horizons in Cancer Therapeutics: From Bench to Bedside 2002;3(2):4–15.
   Google Scholar
• Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. ZD6126: A novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002;54(5):1497–1502.
   PubMed Web of Science ®Google Scholar
• Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62(24):7247–7253.
   PubMed Web of Science ®Google Scholar
• Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, et al. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 2002;62(13):3711–3715.
   PubMed Web of Science ®Google Scholar
• Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999;81(8):1318–1327.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100(12):2491–2499.
   PubMed Web of Science ®Google Scholar
• Strecker TE, Odutola SO, Lopez R, Cooper MS, Tidmore JK, Charlton-Sevcik AK, et al. The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts. Cancer Lett 2015;369(1):229–241.
   PubMed Web of Science ®Google Scholar
• Yao N, Gao M, Ren K, Jiang X, Li Y, Jiang C, et al. PD806: A novel oral vascular disrupting agent shows antitumor and antivascular effects in vitro and in vivo. Anticancer Drugs 2015;26(2):148–159.
   PubMed Web of Science ®Google Scholar
• Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2001;21(1a):93–102.
   PubMed Web of Science ®Google Scholar
• Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003;89(7):1334–1344.
   PubMed Web of Science ®Google Scholar
• Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: The development of combretastatin A4. Lancet Oncol 2001;2(2):82–87.
   PubMedGoogle Scholar
• Chase DM, Chaplin DJ, Monk BJ. The development and use of vascular targeted therapy in ovarian cancer. Gynecol Oncol 2017;145(2):393–406.
   PubMed Web of Science ®Google Scholar
• Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998;77(11):1761–1767.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 1998;42(4);895–898.
   PubMed Web of Science ®Google Scholar
• Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21(15):2823–2830.
   PubMed Web of Science ®Google Scholar
• Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 1999;59(7):1626–1634.
   PubMed Web of Science ®Google Scholar
• Baguley BC, Siemann DW. Temporal aspects of the action of ASA404 (vadimezan; DMXAA). Expert Opin Investig Drugs 2010;19(11):1413–1425.
   PubMed Web of Science ®Google Scholar
• Kim S, Peshkin L, Mitchison TJ. Vascular disrupting agent drug classes differ in effects on the cytoskeleton. PLoS One 2012;7(7):e40177.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009;18(2):189–197.
   PubMed Web of Science ®Google Scholar
• Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62(12):3408–3416.
   PubMed Web of Science ®Google Scholar
• Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21(23):4428–4438.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results. J Clin Oncol 2003;21(15):2815–2822.
   PubMed Web of Science ®Google Scholar
• Akerly W, Schabel M, Morrell G. A randomized phase 2 trial of combretatstatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies. Am Soc Clin Oncol Annu Meeting 2007;25:14060–14060.
   Google Scholar
• Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21(15):2831–2842.
   PubMed Web of Science ®Google Scholar
• Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res 2012;18(12):3428–3439.
   PubMed Web of Science ®Google Scholar
• Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4(3):141–148.
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Douillard JY, Nakagawa K, von PawelJ, McKeage MJ, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011;29(22):2965–2971.
   PubMed Web of Science ®Google Scholar
• Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br J Cancer 2002;86(12):1937–1942.
   PubMed Web of Science ®Google Scholar
• Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004;90(4):906–910.
   PubMed Web of Science ®Google Scholar
• Zhao L, Ching LM, Kestell P, Kelland LR, Baguley BC. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer 2005;116(2):322–326.
   PubMed Web of Science ®Google Scholar
• Sandler HM, Curran WJ Jr, Turrisi AT. 3rd The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1990;19(1);9–13.
   PubMed Web of Science ®Google Scholar
• Brown SL, Kolozsvary A, Kim JH. Vascular targeting therapies for treatment of malignant disease. Cancer 2005;104(1):216–217; author reply 217.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 2004;60(4):1233–1240.
   PubMed Web of Science ®Google Scholar
• Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275(5299):547–550.
   PubMed Web of Science ®Google Scholar
• Horsman MR. Tissue physiology and the response to heat. Int J Hyperthermia 2006;22(3):197–203.
   PubMed Web of Science ®Google Scholar
• Denekamp J, Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol 1991;20(Suppl 1):103–112.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao Z, Shen S, Zhang C, Guo S, Lu Y, et al. Selective depletion of tumor neovasculature by microbubble destruction with appropriate ultrasound pressure. Int J Cancer 2015;137(10):2478–2491.
   PubMed Web of Science ®Google Scholar
• Tempany CM, McDannold NJ, Hynynen K, Jolesz FA. Focused ultrasound surgery in oncology: Overview and principles. Radiology 2011;259(1):39–56.
   PubMed Web of Science ®Google Scholar
• Berbeco RI, Detappe A, Tsiamas P, Parsons D, Yewondwossen M, Robar J. Low Z target switching to increase tumor endothelial cell dose enhancement during gold nanoparticle-aided radiation therapy. Med Phys 2016;43(1):436–442.
   PubMed Web of Science ®Google Scholar
• Mason RP, Antich PP, Babcock EE, Constantinescu A, Peschke P, Hahn EW. Non-invasive determination of tumor oxygen tension and local variation with growth. Int J Radiat Oncol Biol Phys 1994;29(1):95–103.
   PubMed Web of Science ®Google Scholar
• Zhao D, Chang CH, Kim JG, Liu H, Mason RP. In vivo near-infrared spectroscopy and MRI monitoring of tumor response to Combretastatin A-4-phosphate correlated with therapeutic outcome. Int J Radiat Oncol Biol Phys 2011;80(2):574––581.
   PubMed Web of Science ®Google Scholar
• Flynn BL, Gill GS, Grobelny DW, Chaplin JH, Paul D, Leske AF, et al. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem 2011;54(17):6014–6027.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, et al. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer 2013;81(3):422–427.
   PubMed Web of Science ®Google Scholar
• Nervi C, Arcangeli G, Badaracco G, Cortese M, Morelli M, Starace G. The relevance of tumor size and cell kinetics as predictors of radiation response in head and neck cancer. A randomized study on the effect of intraarterial chemotherapy followed by radiotherapy. Cancer 1978;41(3):900–906.
   PubMed Web of Science ®Google Scholar
• Lee CC, Ho HC, Su YC, Lee MS, Hsiao SH, Hwang JH, et al. Bidimensional measurement of nasopharyngeal carcinoma: A simple method to predict outcomes. Clin Otolaryngol 2009;34(1):26–33.
   PubMed Web of Science ®Google Scholar
• Gerber DE, Dahlberg SE, Sandler AB, Ahn DH, Schiller JH, et al. Baseline tumour measurements predict survival in advanced non-small cell lung cancer. Br J Cancer 2013;109(6):14761481.
   Web of Science ®Google Scholar
• Li C, Oh SJ, Kim S, Hyung WJ, Yan M, Zhu ZG, et al. Risk factors of survival and surgical treatment for advanced gastric cancer with large tumor size. J Gastrointest Surg 2009;13(5):881–885.
   PubMed Web of Science ®Google Scholar
• Baldwin NJ, Ng TC. Oxygenation and metabolic status of KHT tumors as measured simultaneously by 19F magnetic resonance imaging and 31P magnetic resonance spectroscopy. Magn Reson Imaging 1996;14(5):541–551.
   PubMed Web of Science ®Google Scholar
• Bentzen L, Keiding S, Horsman MR, Gronroos T, Hansen SB, OvergaardJ. Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing. Acta Oncol 2002;41(3);304–312.
   PubMed Web of Science ®Google Scholar
• Hill RP. An appraisal of in vivo assays of excised tumours. Br J Cancer Suppl 1980;4:230–239.
   PubMedGoogle Scholar
• Kallman RF, DeNardo GL, Stasch MJ. Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. Cancer Res 1972;32(3):483–490.
   PubMed Web of Science ®Google Scholar
• Pallavicini MG, Lalande ME, Miller RG, Hill RP. Cell cycle distribution of chronically hypoxic cells and determination of the clonogenic potential of cells accumulated in G2 + M phases after irradiation of a solid tumor in vivo. Cancer Res 1979;39(6Pt 1):1891–1897.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Johansen IM, Horsman MR. Radiobiological hypoxia in the KHT sarcoma: Predictions using the Eppendorf histograph. Int J Radiat Oncol Biol Phys 199840(5):1171–1176.
   PubMed Web of Science ®Google Scholar
• Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53(2):113–117.
   PubMed Web of Science ®Google Scholar
• Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26(1):45–50.
   PubMed Web of Science ®Google Scholar
• Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41(1):31–39.
   PubMed Web of Science ®Google Scholar
• Durand RE. Keynote address: The influence of microenvironmental factors on the activity of radiation and drugs. Int J Radiat Oncol Biol Phys 1991;20(2):253–258.
   PubMed Web of Science ®Google Scholar
• Landuyt W, Ahmed B, Nuyts S, Theys J, Op de Beeck M, Rijnders A, et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 2001;49(2);443–450.
   PubMed Web of Science ®Google Scholar
• Nielsen T, Murata R, Maxwell RJ, Stodkilde-Jorgensen H, Ostergaard L, Ley CD, et al. Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates. Acta Oncol 2010;49(7):906–913.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;53(1):164–171.
   PubMed Web of Science ®Google Scholar
• Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J, et al. Vascular targeting of solid tumours: A major ‘inverse’ volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 2000;36(14):1833–1843.
   PubMed Web of Science ®Google Scholar
• Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002;8(6):1974–1983.
   PubMed Web of Science ®Google Scholar
• Jain RK. Transport of molecules in the tumor interstitium: A review. Cancer Res 1987;47(12):3039–3051.
   PubMed Web of Science ®Google Scholar
• Heist R, Aren OS, Mita AC, Polikoff J, Bazhenova L, Lloyd GK, et al. Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC). ASCO Annu Meeting 2014;32(5s), (J Clin Oncol suppl; abstr 8054).
   Google Scholar
• Tewari KS, Abrouk NED, Coleman RL, Aghajanian C, Couchenour R, Nelson J, et al. Improved progression-free survival among women with measurable recurrent ovarian carcinoma treated with CA4P plus bevacizumab: A post-hoc analysis of GOG-0186I. IGCS Lisbon, Portugal, 2016; Lisbon, Portugal, 2016.
   Google Scholar
• Bazhenova L. Randomized Phase 2 study of plinabulin and docetaxel in patients with advanced non-small cell lung cancer – mechanism-based efficacy analyses. 16th World Conference on Lung Cancer, Denver, Colorado, USA, 2015; Denver, Colorado, USA, 2015; (abstr. P3.01-057).
   Google Scholar
• Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth. Cancer Chemother Pharmacol 2007;59(6):725–732.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: An adjuvant strategy for radiation therapy. Radiother Oncol 2000;57(1):5–12.
   PubMed Web of Science ®Google Scholar
• Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid 2014;24(2):232–240.
   PubMed Web of Science ®Google Scholar
• Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 201122(9):2036–2041.
   PubMed Web of Science ®Google Scholar
• Ng QS, Mandeville H, Goh V, Alonzi R, Milner J, Carnell D, et al. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol 2012;23(1):231–227.
   PubMed Web of Science ®Google Scholar
• Hensel JA, Flaig TW, Theodorescu D. Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol 2013;10(1):41–51.
   PubMed Web of Science ®Google Scholar
• Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 2006;12(13):4090–4094.
   PubMed Web of Science ®Google Scholar
• LiaoF, Li Y, O'Connor W, Zanetta L, Bassi R, Santiago A, et al. Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res 2000;60(24):6805–6810.
   PubMed Web of Science ®Google Scholar
• O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79(2):315–328.
   PubMed Web of Science ®Google Scholar
• Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, et al. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 1999;59(24):6251–6256.
   PubMed Web of Science ®Google Scholar
• Wedge SRK,   J, Ogilvie DJ, Hennequin LF, Brave AJ, Ryan AJ, Ashton SE, et al. Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced anti-tumor response. Proc Am Assoc Cancer Res 2002(43):1081.
   Google Scholar
• Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008;28(4b):20272031.
   Web of Science ®Google Scholar
• Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, et al. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 2010;116(9):1539–1547.
   PubMed Web of Science ®Google Scholar
• Sheng Y, Hua J, Pinney KG, Garner CM, Kane RR, Prezioso JA, et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 2004;111(4):604–610.
   PubMed Web of Science ®Google Scholar
• Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313(5794):1785–1787.
   PubMed Web of Science ®Google Scholar
• Del Conte G, Bahleda R, Moeno V, Damian S, Perotti A, Lassau N, et al. A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors (NCT01193595). American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2012; Chicago, IL 2012; Abstract 3080.
   Google Scholar
• Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, et al. Randomized Phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: An NRG Oncology/Gynecologic oncology group study. J Clin Oncol 2016;34(19):2279–2286.
   PubMed Web of Science ®Google Scholar
• Garon EB, Neidhart JD, Gabrail NY, de Oliveira M, Balkissoon J, Kabbinavar F. A randomized Phase II trial of the tumor vascular disrupting agent ca4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. Onco Targets Therapy 2016;(9):1–9.
   Google Scholar
• Monk BJ, Herzog T, Alvarez R, Chan J, Chase D, Couchenour R, et al. Focus study: Physician's choice chemotherapy (PCC) plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo in platinum-resistant ovarian cancer. ICGS Journal. Int J Gynecol Cancer. 2016;26:878–878.
   Google Scholar